Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · IEX Real-Time Price · USD
2.390
-0.020 (-0.83%)
At close: Mar 28, 2024, 4:00 PM
2.400
+0.010 (0.42%)
After-hours: Mar 28, 2024, 7:43 PM EDT
Galectin Therapeutics Market Cap
Galectin Therapeutics has a market cap or net worth of $147.82 million as of March 28, 2024. Its market cap has increased by 26.23% in one year.
Market Cap
147.82M
Enterprise Value
188.60M
1-Year Change
26.23%
Ranking
Category
Stock Price
$2.39
Market Cap Chart
Since September 9, 2002, Galectin Therapeutics's market cap has increased from $31.60M to $147.82M, an increase of 367.78%. That is a compound annual growth rate of 7.42%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 28, 2024 | 147.80M | -0.87% |
Mar 27, 2024 | 149.10M | 1.71% |
Mar 26, 2024 | 146.60M | 1.73% |
Mar 25, 2024 | 144.10M | -4.51% |
Mar 22, 2024 | 150.90M | - |
Mar 21, 2024 | 150.90M | 10.87% |
Mar 20, 2024 | 136.10M | 4.77% |
Mar 19, 2024 | 129.90M | -1.89% |
Mar 18, 2024 | 132.40M | 3.92% |
Mar 15, 2024 | 127.40M | 4.00% |
Mar 14, 2024 | 122.50M | - |
Mar 13, 2024 | 122.50M | 0.57% |
Mar 12, 2024 | 121.80M | -2.01% |
Mar 11, 2024 | 124.30M | -1.51% |
Mar 8, 2024 | 126.20M | -2.40% |
Mar 7, 2024 | 129.30M | 0.54% |
Mar 6, 2024 | 128.60M | 0.94% |
Mar 5, 2024 | 127.40M | 3.49% |
Mar 4, 2024 | 123.10M | 3.10% |
Mar 1, 2024 | 119.40M | -1.24% |
Feb 29, 2024 | 120.90M | 3.42% |
Feb 28, 2024 | 116.90M | 1.65% |
Feb 27, 2024 | 115.00M | -1.12% |
Feb 26, 2024 | 116.30M | - |
Feb 23, 2024 | 116.30M | 5.63% |
View and export this data all the way back to 2002.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Telomir Pharmaceuticals | 157.64M |
Achieve Life Sciences | 155.67M |
Allurion Technologies | 153.33M |
Xtant Medical Holdings | 150.93M |
I-Mab | 150.10M |
CytomX Therapeutics | 148.99M |
Acrivon Therapeutics | 148.26M |
Armata Pharmaceuticals | 148.20M |